Alseres Pharmaceuticals, Inc.
Alseres Pharmaceuticals, Inc. (ALSE) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
alse · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 5 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Alseres Pharmaceuticals, Inc.You ALSE | $0M | N/A | — | -$153.75 |
 Achiko AG ACHKF | $0M | N/A | — | -$0.07 |
 Digicann Ventures Inc. AGFAF | $0M | N/A | — | -$0.02 |
 Aquarius Surgical Technologies Inc. AQQRF | $0M | N/A | — | -$0.04 |
 Evolva Holding S.A. ELVAY | $1M | 1302.74x | — | $0.14 |
 FluroTech Ltd. FLURF | $0M | N/A | — | -$0.00 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Alseres Pharmaceuticals, Inc. (ALSE) measures how much investors pay for each dollar of the company's trailing earnings. ALSE's current PE ratio of N/A is calculated by dividing its stock price of $0.01 by its TTM earnings per share of -$153.75.
Frequently asked questions
ALSE pe ratio · 6 questionsALSE's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.01 and TTM EPS of -$153.75. Data sourced from Financial Modeling Prep via ALSE's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Alseres Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09